83 FR 19075 - Agency Information Collection Activities: Proposed Collection; Comment Request
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration Federal Register Volume 83, Issue 84 (May 1, 2018)
Substance Abuse and Mental Health Services Administration
Federal Register Volume 83, Issue 84 (May 1, 2018)
| Page Range | 19075-19076 | |
| FR Document | 2018-09146 |
[Federal Register Volume 83, Number 84 (Tuesday, May 1, 2018)] [Notices] [Pages 19075-19076] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-09146] [[Page 19075]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer at (240) 276-1243. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Government Performance and Results Act (GPRA) Client/ Participant Outcomes Measure--(OMB No. 0930-0208)--Revision SAMHSA is requesting approval to add 13 new questions to its existing CSAT Client-level GPRA instrument. Grantees will only be required to answer no more than four additional questions, per CSAT grant awarded, in addition to the other questions on the instrument. Currently, the information collected from this instrument is entered and stored in SAMSHA's Performance Accountability and Reporting System, which is a real-time, performance management system that captures information on the substance abuse treatment and mental health services delivered in the United States. Continued approval of this information collection will allow SAMHSA to continue to meet Government Performance and Results Modernization Act of 2010 reporting requirements that quantify the effects and accomplishments of its discretionary grant programs, which are consistent with OMB guidance. SAMHSA and its Centers will use the data for annual reporting required by GPRA and comparing baseline with discharge and follow-up data. GPRA requires that SAMHSA's fiscal year report include actual results of performance monitoring for the three preceding fiscal years. The additional information collected through this process will allow SAMHSA to: (1) Report results of these performance outcomes; (2) maintain consistency with SAMHSA-specific performance domains, and (3) assess the accountability and performance of its discretionary and formula grant programs. Proposed changes include the addition of 13 questions to the instrument. The proposed questions are: 1. Behavioral Health Diagnoses--Please indicate patient's current behavioral health diagnoses using the International Statistical Classification of Diseases, 10th revision, Clinical Modification (ICD- 10-CM) codes listed below: (Select from list of Substance Use Disorder Diagnoses and Mental Health Diagnoses) 2. [For grantee, at discharge and follow-up] Which of the following occurred for the client, as a result of receiving treatment? a. Client was reunited with child (children) b. Client avoided out of home placement for child (children) c. None of the above 3. [For grantee] Please indicate the following: a. Was this client diagnosed with an opioid use disorder? (Yes/No) i. If yes, indicate which FDA-approved medication the client received for the treatment of opioid use disorder. (Methadone, Buprenorphine, Naltrexone, Extended-release naltrexone, Client did not receive an FDA-approved medication for opioid use disorder) 1. If client received an FDA-approved medication for opioid use disorder, indicate the number of days the client received medication. b. Was the client diagnosed with an alcohol use disorder? (Yes/No) i. If yes, indicate which FDA-approved medication the client received for alcohol use disorder. (Naltrexone, Extended-release Naltrexone, Disulfiram, Acamprosate, Client did not receive an FDA- approved medication for alcohol use disorder) 1. If client received an FDA-approved medication for alcohol use disorder, indicate the number of days the client received medication 4. [For client] Did the [insert grantee name] help you obtain any of the following benefits? a. Private health insurance b. Medicaid c. SSI/SSDI d. TANF e. SNAP 5. [For client] Which of the following were achieved as a result of receiving services or supports from [insert grantee name]? a. Enrolled in school b. Enrolled in vocational training c. Currently employed d. Living in stable housing 6. [For client] Please indicate the degree to which you agree or disagree with the following statement (Strongly Disagree, Disagree, Undecided, Agree, Strongly Agree). a. Receiving treatment in a non-residential setting has enabled me to maintain parenting and family responsibilities while receiving treatment. 7. [For client] Please indicate the degree to which you agree or disagree with the following statement (Strongly Disagree, Disagree, Undecided, Agree, Strongly Agree). a. Receiving treatment in a residential setting with my child (children) enabled me to focus on my treatment without the distractions of parenting and family responsibilities. b. As a result of treatment, I feel I now have the skills and supports to balance parenting and managing my recovery. 8. [For grantee] Please indicate which type of funding was/will be used to pay for the SBIRT services provided to this client. (check all that apply): a. Current SAMHSA grant funding b. Other federal grant funding c. State funding d. Client's private insurance e. Medicaid/Medicare f. Other (Specify) 9. [For grantee at baseline] If client screened positive for substance misuse or a substance use disorder, was the client assigned to the following types of services? 1. Brief Intervention (Yes/No) 2. Brief Treatment (Yes/No) 3. Referral to Treatment (Yes/No) [For grantee at follow-up and discharge] Did the client receive the following types of services? 1. Brief Intervention (Yes/No) 2. Brief Treatment (Yes/No) [[Page 19076]] 3. Referral to Treatment (Yes/No) 10. [For grantee] Did this client get screened and referred to treatment for an opioid use disorder or an alcohol use disorder? Yes/No a. If yes, did they receive an FDA-approved medication for the treatment of opioid use disorder or alcohol use disorder? Yes/No i. If yes, specify the FDA-approved medication (methadone, buprenorphine, naltrexone, extended-release naltrexone) for opioid use disorder. ii. If yes, specify the FDA-approved medication (naltrexone, extended-release naltrexone, disulfiram, acamprosate) for alcohol use disorder. 11. [For client] Did the program provide the following: (Asked of client at follow up) a. HIV test--Yes/No i. If yes, the result was--Positive/Negative/Indeterminate/Don't know ii. If the result was Positive were you connected to treatment services--Yes/No b. Hepatitis B (HBV) test--Yes/No i. If yes, the result was--Positive/Negative/Indeterminate/Don't know ii. If the result was Positive were you connected to treatment services--Yes/No c. Hepatitis C (HCV) test--Yes/No i. If yes, the result was--Positive/Negative/Indeterminate/Don't know ii. If the result was Positive were you connected to treatment services--Yes/No 12. [For client] Indicate the degree to which you agree or disagree with each of the following statements by using: Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree, Not Applicable a. The use of technology accessed through (insert grantee or program name) helped me i. Communicate with my provider ii. Reduce my substance use iii. Manage my mental health symptoms iv. Support my recovery 13. [For client] To what extent has this program improved your quality of life? (To a Great Extent, Somewhat, Very Little, Not at All) Table 1--Estimates of Annualized Hour Burden ---------------------------------------------------------------------------------------------------------------- Number of Responses per Total number Burden hours Total burden SAMHSA tool respondents respondent of responses per response hours ---------------------------------------------------------------------------------------------------------------- Baseline Interview Includes 179,668 1 179,668 0.60 107,801 SBIRT Brief TX, Referral to TX, and Program-specific questions. Follow-Up Interview with Program- 143,734 1 143,734 0.60 86,240 specific questions \1\......... Discharge Interview with Program- 93,427 1 93,427 0.60 56,056 specific questions \2\......... SBIRT Program--Screening Only... 594,192 1 594,192 0.13 77,245 SBIRT Program--Brief 111,411 1 111,411 .20 22,282 Intervention Only Baseline..... SBIRT Program--Brief 89,129 1 89,129 .20 17,826 Intervention Only Follow-Up \1\ SBIRT Program--Brief 57,934 1 57,934 .20 11,587 Intervention Only Discharge \2\ ------------------------------------------------------------------------------- CSAT Total.................. 885,271 .............. 1,269,495 .............. 379,037 ---------------------------------------------------------------------------------------------------------------- Note: Numbers may not add to the totals due to rounding and some individual participants completing more than one form. \1\ It is estimated that 80% of baseline clients will complete this interview. \2\ It is estimated that 52% of baseline clients will complete this interview. Send comments to Summer King, SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a copy to summer.king@samhsa.hhs.gov. Written comments should be received by July 2, 2018. Summer King, Statistician. [FR Doc. 2018-09146 Filed 4-30-18; 8:45 am] BILLING CODE 4162-20-P
![Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices 19075
DEPARTMENT OF HEALTH AND grant programs, which are consistent indicate the number of days the
HUMAN SERVICES with OMB guidance. client received medication
SAMHSA and its Centers will use the 4. [For client] Did the [insert grantee
Substance Abuse and Mental Health data for annual reporting required by name] help you obtain any of the
Services Administration GPRA and comparing baseline with following benefits?
discharge and follow-up data. GPRA a. Private health insurance
Agency Information Collection requires that SAMHSA’s fiscal year
Activities: Proposed Collection; b. Medicaid
report include actual results of c. SSI/SSDI
Comment Request performance monitoring for the three d. TANF
preceding fiscal years. The additional e. SNAP
In compliance with Section information collected through this
3506(c)(2)(A) of the Paperwork 5. [For client] Which of the following
process will allow SAMHSA to: (1)
Reduction Act of 1995 concerning were achieved as a result of receiving
Report results of these performance
opportunity for public comment on services or supports from [insert grantee
outcomes; (2) maintain consistency with
proposed collections of information, the name]?
SAMHSA-specific performance
Substance Abuse and Mental Health domains, and (3) assess the a. Enrolled in school
Services Administration (SAMHSA) accountability and performance of its b. Enrolled in vocational training
will publish periodic summaries of discretionary and formula grant c. Currently employed
proposed projects. To request more programs. d. Living in stable housing
information on the proposed projects or Proposed changes include the 6. [For client] Please indicate the
to obtain a copy of the information addition of 13 questions to the degree to which you agree or disagree
collection plans, call the SAMHSA instrument. The proposed questions are: with the following statement (Strongly
Reports Clearance Officer at (240) 276– 1. Behavioral Health Diagnoses— Disagree, Disagree, Undecided, Agree,
1243. Please indicate patient’s current Strongly Agree).
Comments are invited on: (a) Whether behavioral health diagnoses using the a. Receiving treatment in a non-
the proposed collections of information International Statistical Classification of residential setting has enabled me
are necessary for the proper Diseases, 10th revision, Clinical to maintain parenting and family
performance of the functions of the Modification (ICD–10–CM) codes listed responsibilities while receiving
agency, including whether the below: (Select from list of Substance treatment.
information shall have practical utility; Use Disorder Diagnoses and Mental 7. [For client] Please indicate the
(b) the accuracy of the agency’s estimate Health Diagnoses) degree to which you agree or disagree
of the burden of the proposed collection 2. [For grantee, at discharge and with the following statement (Strongly
of information; (c) ways to enhance the follow-up] Which of the following Disagree, Disagree, Undecided, Agree,
quality, utility, and clarity of the occurred for the client, as a result of Strongly Agree).
information to be collected; and (d) receiving treatment? a. Receiving treatment in a residential
ways to minimize the burden of the a. Client was reunited with child setting with my child (children)
collection of information on (children) enabled me to focus on my
respondents, including through the use b. Client avoided out of home placement treatment without the distractions
of automated collection techniques or for child (children) of parenting and family
other forms of information technology. c. None of the above responsibilities.
Proposed Project: Government 3. [For grantee] Please indicate the b. As a result of treatment, I feel I now
Performance and Results Act (GPRA) following: have the skills and supports to
Client/Participant Outcomes Measure— a. Was this client diagnosed with an balance parenting and managing my
(OMB No. 0930–0208)—Revision opioid use disorder? (Yes/No) recovery.
i. If yes, indicate which FDA- 8. [For grantee] Please indicate which
SAMHSA is requesting approval to approved medication the client type of funding was/will be used to pay
add 13 new questions to its existing received for the treatment of opioid for the SBIRT services provided to this
CSAT Client-level GPRA instrument. use disorder. (Methadone, client. (check all that apply):
Grantees will only be required to answer Buprenorphine, Naltrexone, a. Current SAMHSA grant funding
no more than four additional questions, Extended-release naltrexone, Client b. Other federal grant funding
per CSAT grant awarded, in addition to did not receive an FDA-approved c. State funding
the other questions on the instrument. medication for opioid use disorder) d. Client’s private insurance
Currently, the information collected 1. If client received an FDA-approved e. Medicaid/Medicare
from this instrument is entered and medication for opioid use disorder, f. Other (Specify)
stored in SAMSHA’s Performance indicate the number of days the 9. [For grantee at baseline] If client
Accountability and Reporting System, client received medication. screened positive for substance misuse
which is a real-time, performance b. Was the client diagnosed with an
or a substance use disorder, was the
management system that captures alcohol use disorder? (Yes/No)
client assigned to the following types of
information on the substance abuse i. If yes, indicate which FDA-
services?
treatment and mental health services approved medication the client
delivered in the United States. received for alcohol use disorder. 1. Brief Intervention (Yes/No)
2. Brief Treatment (Yes/No)
amozie on DSK30RV082PROD with NOTICES
Continued approval of this information (Naltrexone, Extended-release
collection will allow SAMHSA to Naltrexone, Disulfiram, 3. Referral to Treatment (Yes/No)
continue to meet Government Acamprosate, Client did not receive [For grantee at follow-up and
Performance and Results Modernization an FDA-approved medication for discharge] Did the client receive the
Act of 2010 reporting requirements that alcohol use disorder) following types of services?
quantify the effects and 1. If client received an FDA-approved 1. Brief Intervention (Yes/No)
accomplishments of its discretionary medication for alcohol use disorder, 2. Brief Treatment (Yes/No)
VerDate Sep<11>2014 18:12 Apr 30, 2018 Jkt 244001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\01MYN1.SGM 01MYN1](https://thefederalregister.org/doc/83_FR_19159/page/1.svg)
![19076 Federal Register / Vol. 83, No. 84 / Tuesday, May 1, 2018 / Notices
3. Referral to Treatment (Yes/No) 11. [For client] Did the program Yes/No
10. [For grantee] Did this client get provide the following: (Asked of client 12. [For client] Indicate the degree to
screened and referred to treatment for at follow up) which you agree or disagree with each
an opioid use disorder or an alcohol use a. HIV test—Yes/No of the following statements by using:
disorder? Yes/No i. If yes, the result was—Positive/ Strongly Disagree, Disagree, Neutral,
a. If yes, did they receive an FDA- Negative/Indeterminate/Don’t know Agree, Strongly Agree, Not Applicable
ii. If the result was Positive were you
approved medication for the a. The use of technology accessed
connected to treatment services—
treatment of opioid use disorder or through (insert grantee or program
Yes/No
alcohol use disorder? Yes/No b. Hepatitis B (HBV) test—Yes/No name) helped me
i. If yes, specify the FDA-approved i. If yes, the result was—Positive/ i. Communicate with my provider
medication (methadone, Negative/Indeterminate/Don’t know ii. Reduce my substance use
buprenorphine, naltrexone, ii. If the result was Positive were you
extended-release naltrexone) for iii. Manage my mental health
connected to treatment services— symptoms
opioid use disorder. Yes/No
ii. If yes, specify the FDA-approved iv. Support my recovery
c. Hepatitis C (HCV) test—Yes/No
medication (naltrexone, extended- i. If yes, the result was—Positive/ 13. [For client] To what extent has
release naltrexone, disulfiram, Negative/Indeterminate/Don’t know this program improved your quality of
acamprosate) for alcohol use ii. If the result was Positive were you life? (To a Great Extent, Somewhat, Very
disorder. connected to treatment services— Little, Not at All)
TABLE 1—ESTIMATES OF ANNUALIZED HOUR BURDEN
Responses Total Burden Total
Number of
SAMHSA tool per number of hours burden
respondents respondent responses per response hours
Baseline Interview Includes SBIRT Brief TX, Referral to
TX, and Program-specific questions ................................ 179,668 1 179,668 0.60 107,801
Follow-Up Interview with Program-specific questions 1 ....... 143,734 1 143,734 0.60 86,240
Discharge Interview with Program-specific questions 2 ....... 93,427 1 93,427 0.60 56,056
SBIRT Program—Screening Only ....................................... 594,192 1 594,192 0.13 77,245
SBIRT Program—Brief Intervention Only Baseline ............. 111,411 1 111,411 .20 22,282
SBIRT Program—Brief Intervention Only Follow-Up 1 ........ 89,129 1 89,129 .20 17,826
SBIRT Program—Brief Intervention Only Discharge 2 ........ 57,934 1 57,934 .20 11,587
CSAT Total ................................................................... 885,271 ........................ 1,269,495 ........................ 379,037
Note: Numbers may not add to the totals due to rounding and some individual participants completing more than one form.
1 It is estimated that 80% of baseline clients will complete this interview.
2 It is estimated that 52% of baseline clients will complete this interview.
Send comments to Summer King, SUMMARY: The Department of Health and FOR FURTHER INFORMATION CONTACT:
SAMHSA Reports Clearance Officer, Human Services (HHS) notifies federal Giselle Hersh, Division of Workplace
5600 Fishers Lane, Room 15E57–B, agencies of the laboratories and Programs, SAMHSA/CSAP, 5600
Rockville, Maryland 20857, OR email a Instrumented Initial Testing Facilities Fishers Lane, Room 16N03A, Rockville,
copy to summer.king@samhsa.hhs.gov. (IITF) currently certified to meet the Maryland 20857; 240–276–2600 (voice).
Written comments should be received standards of the Mandatory Guidelines SUPPLEMENTARY INFORMATION: The
by July 2, 2018. for Federal Workplace Drug Testing Department of Health and Human
Summer King, Programs (Mandatory Guidelines). Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Statistician. A notice listing all currently HHS- Initial Testing Facilities (IITF) currently
[FR Doc. 2018–09146 Filed 4–30–18; 8:45 am] certified laboratories and IITFs is certified to meet the standards of the
BILLING CODE 4162–20–P published in the Federal Register Mandatory Guidelines for Federal
during the first week of each month. If Workplace Drug Testing Programs
any laboratory or IITF certification is (Mandatory Guidelines). The Mandatory
DEPARTMENT OF HEALTH AND suspended or revoked, the laboratory or Guidelines were first published in the
HUMAN SERVICES IITF will be omitted from subsequent Federal Register on April 11, 1988 (53
lists until such time as it is restored to FR 11970), and subsequently revised in
Substance Abuse and Mental Health
full certification under the Mandatory the Federal Register on June 9, 1994 (59
Services Administration
Guidelines. FR 29908); September 30, 1997 (62 FR
Current List of HHS-Certified If any laboratory or IITF has 51118); April 13, 2004 (69 FR 19644);
Laboratories and Instrumented Initial withdrawn from the HHS National November 25, 2008 (73 FR 71858);
Testing Facilities Which Meet Minimum Laboratory Certification Program (NLCP) December 10, 2008 (73 FR 75122); April
amozie on DSK30RV082PROD with NOTICES
Standards To Engage in Urine Drug during the past month, it will be listed 30, 2010 (75 FR 22809); and on January
Testing for Federal Agencies 23, 2017 (82 FR 7920)
at the end and will be omitted from the The Mandatory Guidelines were
monthly listing thereafter. initially developed in accordance with
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS. This notice is also available on the Executive Order 12564 and section 503
internet at http://www.samhsa.gov/ of Public Law 100–71. The ‘‘Mandatory
ACTION: Notice.
workplace. Guidelines for Federal Workplace Drug
VerDate Sep<11>2014 18:12 Apr 30, 2018 Jkt 244001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\01MYN1.SGM 01MYN1](https://thefederalregister.org/doc/83_FR_19159/page/2.svg)
Document Created: 2018-05-01 00:24:39
Document Modified: 2018-05-01 00:24:39
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 83 FR 19075 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR